Statements (52)
Predicate | Object |
---|---|
gptkbp:instanceOf |
mRNA technology
|
gptkbp:aimsTo |
improve immune response
|
gptkbp:develops |
mRNA vaccines
|
gptkbp:focusesOn |
therapeutics
|
gptkbp:hasClient |
global vaccine supply
|
gptkbp:hasCollaboratedWith |
academic institutions
various pharmaceutical companies |
gptkbp:hasFocusOn |
sustainable development
|
gptkbp:hasParticipatedIn |
international collaborations
|
gptkbp:hasRelatedPatent |
vaccine development
treat rare diseases |
https://www.w3.org/2000/01/rdf-schema#label |
CureVac's mRNA platform
|
gptkbp:isAttendedBy |
mRNA delivery methods
vaccine_hesitancy |
gptkbp:isBasedOn |
lipid nanoparticle delivery system
nucleic acid technology |
gptkbp:isChallengedBy |
new therapeutic modalities
|
gptkbp:isConsidered |
next-generation vaccine platform
|
gptkbp:isDesignedFor |
target specific antigens
|
gptkbp:isEnhancedBy |
patient outcomes
vaccine efficacy global health security vaccine safety |
gptkbp:isExemplifiedBy |
combination therapies
|
gptkbp:isFacilitatedBy |
rapid vaccine development
|
gptkbp:isFocusedOn |
personalized medicine
|
gptkbp:isIncorporatedIn |
synthetic biology
|
gptkbp:isIntegratedWith |
machine learning
|
gptkbp:isLedBy |
data analytics
|
gptkbp:isLocatedIn |
clinical data
bioinformatics tools |
gptkbp:isPartOf |
global health initiatives
biotechnology industry CureVac's_product_pipeline |
gptkbp:isPromotedBy |
public health
|
gptkbp:isRegulatedBy |
health authorities
|
gptkbp:isSimilarTo |
reduce disease burden
|
gptkbp:isSupportedBy |
scientific research
vaccine equity |
gptkbp:isTargetedAt |
autoimmune diseases
|
gptkbp:isUsedFor |
therapeutic proteins
|
gptkbp:isUsedIn |
cancer treatment
infectious disease treatment |
gptkbp:isUtilizedFor |
immune modulation
|
gptkbp:isUtilizedIn |
clinical trials
vaccine research vaccine technology |
gptkbp:isVisitedBy |
gptkb:CureVac_AG
gptkb:COVID-19_vaccine |
gptkbp:translatedInto |
traditional vaccine approaches
healthcare_delivery |
gptkbp:utilizes |
messenger RNA
|